

EQA round: AIM2/23 - Autoimmunity

Deadline: 2.10.2023

Setup: groups - measurement principle

AV = assigned value

N_{tot} = total number of the resultsN_{eva} = number of the results assessedN_{rel} = relative number of the resultsN_{suc} = number of successful results

>>> ... expected result

S_{rel} = relative success

> ... acceptable result

± ... result not assessed

Test Sample Group	Frequency of the results					Success		
	AV	N _{tot}	N _{rel} [%]	Result	N _{eva}	N _{suc}	S _{rel} [%]	
Set 1								
(560) ANA screening (antibodies against cell nucleus) - prove		78				78	77	99
Sample A1		78				78	78	100
(1) Fluorescent methods	CVP >>>	71	91	Positive				
(2) EIA methods	CVP >>>	6	7,7	Positive				
(99) Another measurement principle	CVP >>>	1	1,3	Positive				
Sample B1		78				78	77	99
(1) Fluorescent methods	CVP >>>	70	90	Negative				
		1	1,3	Positive				
(2) EIA methods	CVP >>>	6	7,7	Negative				
(99) Another measurement principle	CVP >>>	1	1,3	Negative				
(572) ANA screening (antibodies against cell nucleus) - semi-quantity		67				0		
Sample A1		67				0		
(0) Not specified	±	2	3	titre 40				
	±	1	1,5	titre 320				
	±	8	12	titre 640				
	±	39	58	titre 1280				
	±	17	25	titre 2560				
Sample B1		67				0		
(0) Not specified	±	52	78	titre 0 (not measurable)				
	±	10	15	titre 40				
	±	4	6	titre 80				
	±	1	1,5	titre 160				
(561) ANA - type of fluorescence - nucleus		71				71	69	97
Sample A1		71				71	71	100
(0) Not specified	CVP >>>	69	97	Coarse or fine speckled				
	>	2	2,8	Coarse or fine speckled; Nuclear matrix				
Sample B1		71				71	69	97
(0) Not specified		1	1,4	Not specified				
	CVP >>>	69	97	No fluorescence				
		1	1,4	Coarse or fine speckled				
(563) ANA screening (antibodies against cytoplasm) - prove		70				70	64	91
Sample A1		70				70	65	93
(1) Fluorescent methods	CVP >>>	65	93	Negative				
		2	2,9	Inconclusive result (borderline)				
		3	4,3	Positive				
Sample B1		70				70	69	99
(1) Fluorescent methods	CVP >>>	69	99	Negative				
		1	1,4	Positive				
(573) ANA screening (antibodies against cytoplasm) - semi-quantity		65				0		
Sample A1		65				0		
(0) Not specified	±	47	72	titre 0 (not measurable)				
	±	10	15	titre 40				
	±	7	11	titre 80				
	±	1	1,5	titre 160				
Sample B1		65				0		
(0) Not specified	±	1	1,5	Not specified				
	±	50	77	titre 0 (not measurable)				
	±	10	15	titre 40				
	±	4	6,2	titre 80				
(564) ANA - type of fluorescence - cytoplasm		69				69	63	91
Sample A1		69				69	64	93
(0) Not specified	CVP >>>	64	93	No fluorescence				
		4	5,8	Fine speckled cytoplasmic pattern				
		1	1,4	Diffusion cytoplasmic picture				
Sample B1		69				69	68	99
(0) Not specified	CVP >>>	68	99	No fluorescence				
		1	1,4	Diffusion cytoplasmic picture				

Test Sample Group	Frequency of the results				Success		
	AV	N _{tot}	N _{rel} [%]	Result	N _{eva}	N _{suc}	S _{rel} [%]
Set 2							
(565) ANCA imunofluorescence - prove		65			65	65	100
Sample A2		65			65	65	100
(0) Not specified	CVP >>>	1	1,5	Negative			
(1) Fluorescent met. (ethanol)	CVP >>>	48	74	Negative			
(2) Fluorescent met. (formalin)	CVP >>>	6	9,2	Negative			
(99) Another measurement principle	CVP >>>	10	15	Negative			
Sample B2		65			65	65	100
(0) Not specified	CVP >>>	1	1,5	Positive			
(1) Fluorescent met. (ethanol)	CVP >>>	48	74	Positive			
(2) Fluorescent met. (formalin)	CVP >>>	6	9,2	Positive			
(99) Another measurement principle	CVP >>>	10	15	Positive			
(574) ANCA IF (ethanol) - semi-quantity		55			0		
Sample A2		55			0		
(0) Not specified	±	45	82	titre 0 (not measurable)			
	±	9	16	titre 20			
	±	1	1,8	titre 40			
Sample B2		55			0		
(0) Not specified	±	3	5,5	titre 20			
	±	1	1,8	titre 40			
	±	3	5,5	titre 80			
	±	6	11	titre 160			
	±	12	22	titre 320			
	±	19	35	titre 640			
	±	8	15	titre 1280			
	±	3	5,5	titre 2560			
(578) ANCA IF (formalin) - semi-quantity		51			0		
Sample A2		51			0		
(0) Not specified	±	43	84	titre 0 (not measurable)			
	±	7	14	titre 20			
	±	1	2	titre 40			
Sample B2		51			0		
(0) Not specified	±	2	3,9	titre 20			
	±	4	7,8	titre 40			
	±	4	7,8	titre 80			
	±	9	18	titre 160			
	±	14	27	titre 320			
	±	13	25	titre 640			
	±	2	3,9	titre 1280			
	±	3	5,9	titre 2560			
(566) ANCA - type of fluorescence		63			63	60	95
Sample A2		63			63	62	98
(0) Not specified	CVP >>>	62	98	No fluorescence			
		1	1,6	NSA (atypical ANCA)			
Sample B2		63			63	61	97
(0) Not specified	CVP >>>	61	97	Perinuclear fluorescence			
		2	3,2	Perinuclear fluorescence; ANA			
(569) anti-myeloperoxidase		73			73	72	99
Sample A2		73			73	72	99
(1) Fluorescent methods	CVP >>>	2	2,7	Negative			
(2) EIA methods	CVP >>>	49	67	Negative			
		1	1,4	Positive			
(5) LIA, ILMA	CVP >>>	10	14	Negative			
(6) Immunoblotting	CVP >>>	8	11	Negative			
(99) Another measurement principle	CVP >>>	3	4,1	Negative			
Sample B2		73			73	73	100
(1) Fluorescent methods	CVP >>>	2	2,7	Positive			
(2) EIA methods	CVP >>>	50	68	Positive			
(5) LIA, ILMA	CVP >>>	10	14	Positive			
(6) Immunoblotting	CVP >>>	8	11	Positive			
(99) Another measurement principle	CVP >>>	3	4,1	Positive			
(570) anti-proteinase III		73			73	73	100
Sample A2		73			73	73	100
(1) Fluorescent methods	CVP >>>	2	2,7	Negative			
(2) EIA methods	CVP >>>	50	68	Negative			
(5) LIA, ILMA	CVP >>>	10	14	Negative			
(6) Immunoblotting	CVP >>>	8	11	Negative			
(99) Another measurement principle	CVP >>>	3	4,1	Negative			

EQA round: AIM2/23 - Autoimmunity

Deadline: 2.10.2023

Setup: groups - measurement principle

Test Sample Group	Frequency of the results					Success		
	AV	N _{tot}	N _{rel} [%]	Result	N _{eva}	N _{suc}	S _{rel} [%]	
Sample B2		73				73	73	100
(1) Fluorescent methods	CVP >>>	2	2,7	Negative				
(2) EIA methods	CVP >>>	50	68	Negative				
(5) LIA, ILMA	CVP >>>	10	14	Negative				
(6) Immunoblotting	CVP >>>	8	11	Negative				
(99) Another measurement principle	CVP >>>	3	4,1	Negative				
Set 3								
(585) anti-centromere		75				75	74	99
Sample A3		75				75	75	100
(1) Fluorescent methods	CVP >>>	9	12	Negative				
(2) EIA methods	CVP >>>	19	25	Negative				
(5) LIA, ILMA	CVP >>>	2	2,7	Negative				
(6) Immunoblotting	CVP >>>	42	56	Negative				
(99) Another measurement principle	CVP >>>	3	4	Negative				
Sample B3		75				75	74	99
(1) Fluorescent methods	CVP >>>	8	11	Negative				
		1	1,3	Positive				
(2) EIA methods	CVP >>>	19	25	Negative				
(5) LIA, ILMA	CVP >>>	2	2,7	Negative				
(6) Immunoblotting	CVP >>>	42	56	Negative				
(99) Another measurement principle	CVP >>>	3	4	Negative				
(584) anti-ENA, antigen Jo-1		78				78	78	100
Sample A3		78				78	78	100
(1) Fluorescent methods	CVP >>>	1	1,3	Negative				
(2) EIA methods	CVP >>>	30	38	Negative				
(5) LIA, ILMA	CVP >>>	2	2,6	Negative				
(6) Immunoblotting	CVP >>>	43	55	Negative				
(99) Another measurement principle	CVP >>>	2	2,6	Negative				
Sample B3		78				78	78	100
(1) Fluorescent methods	CVP >>>	1	1,3	Negative				
(2) EIA methods	CVP >>>	30	38	Negative				
(5) LIA, ILMA	CVP >>>	2	2,6	Negative				
(6) Immunoblotting	CVP >>>	43	55	Negative				
(99) Another measurement principle	CVP >>>	2	2,6	Negative				
(583) anti-ENA, antigen RNP		78				78	78	100
Sample A3		78				78	78	100
(1) Fluorescent methods	CVP >>>	1	1,3	Negative				
(2) EIA methods	CVP >>>	30	38	Negative				
(5) LIA, ILMA	CVP >>>	2	2,6	Negative				
(6) Immunoblotting	CVP >>>	43	55	Negative				
(99) Another measurement principle	CVP >>>	2	2,6	Negative				
Sample B3		78				78	78	100
(1) Fluorescent methods	CVP >>>	1	1,3	Negative				
(2) EIA methods	CVP >>>	30	38	Negative				
(5) LIA, ILMA	CVP >>>	2	2,6	Negative				
(6) Immunoblotting	CVP >>>	43	55	Negative				
(99) Another measurement principle	CVP >>>	2	2,6	Negative				
(582) anti-ENA, antigen Scl-70		79				79	78	99
Sample A3		79				79	79	100
(1) Fluorescent methods	CVP >>>	1	1,3	Negative				
(2) EIA methods	CVP >>>	30	38	Negative				
(5) LIA, ILMA	CVP >>>	2	2,5	Negative				
(6) Immunoblotting	CVP >>>	44	56	Negative				
(99) Another measurement principle	CVP >>>	2	2,5	Negative				
Sample B3		79				79	78	99
(1) Fluorescent methods	CVP >>>	1	1,3	Negative				
(2) EIA methods	CVP >>>	30	38	Negative				
(5) LIA, ILMA	CVP >>>	2	2,5	Negative				
(6) Immunoblotting	CVP >>>	43	54	Negative				
		1	1,3	Positive				
(99) Another measurement principle	CVP >>>	2	2,5	Negative				
(580) anti-ENA, antigen SS-A/Ro-60		79				79	79	100
Sample A3		79				79	79	100
(1) Fluorescent methods	CVP >>>	1	1,3	Negative				
(2) EIA methods	CVP >>>	30	38	Negative				
(5) LIA, ILMA	CVP >>>	2	2,5	Negative				
(6) Immunoblotting	CVP >>>	44	56	Negative				
(99) Another measurement principle	CVP >>>	2	2,5	Negative				

EQA round: AIM2/23 - Autoimmunity

Deadline: 2.10.2023

Setup: groups - measurement principle

Test Sample Group	Frequency of the results					Success		
	AV	N _{tot}	N _{rel} [%]	Result	N _{eva}	N _{suc}	S _{rel} [%]	
Sample B3		79				79	79	100
(1) Fluorescent methods	CVP >>>	1	1,3	Positive				
(2) EIA methods	CVP >>>	30	38	Positive				
(5) LIA, ILMA	CVP >>>	2	2,5	Positive				
(6) Immunoblotting	CVP >>>	44	56	Positive				
(99) Another measurement principle	CVP >>>	2	2,5	Positive				
(581) anti-ENA, antigen SS-B/La		79				79	79	100
Sample A3		79				79	79	100
(0) Not specified	CVP >>>	1	1,3	Negative				
(1) Fluorescent methods	CVP >>>	1	1,3	Negative				
(2) EIA methods	CVP >>>	29	37	Negative				
(5) LIA, ILMA	CVP >>>	2	2,5	Negative				
(6) Immunoblotting	CVP >>>	44	56	Negative				
(99) Another measurement principle	CVP >>>	2	2,5	Negative				
Sample B3		79				79	79	100
(0) Not specified	CVP >>>	1	1,3	Positive				
(1) Fluorescent methods	CVP >>>	1	1,3	Positive				
(2) EIA methods	CVP >>>	29	37	Positive				
(5) LIA, ILMA	CVP >>>	2	2,5	Positive				
(6) Immunoblotting	CVP >>>	44	56	Positive				
(99) Another measurement principle	CVP >>>	2	2,5	Positive				
Set 4								
(588) anti-dsDNA immunofluorescence - prove		57				57	57	100
Sample A4		57				57	57	100
(0) Not specified	CVP >>>	57	100	Positive				
Sample B4		57				57	57	100
(0) Not specified	CVP >>>	57	100	Negative				
(577) anti-dsDNA immunofluorescence - semi-quantity		51				0		
Sample A4		51				0		
(0) Not specified	±	1	2	titre 10				
	±	1	2	titre 40				
	±	3	5,9	titre 80				
	±	1	2	titre 160				
	±	11	22	titre 320				
	±	16	31	titre 640				
	±	15	29	titre 1280				
	±	3	5,9	titre 2560				
Sample B4		51				0		
(0) Not specified	±	1	2	Not specified				
	±	41	80	titre 0 (not measurable)				
	±	9	18	titre 10				
(589) anti-dsDNA other methods		63				63	62	98
Sample A4		63				63	62	98
(2) EIA methods		1	1,6	Negative				
	CVP >>>	45	71	Positive				
(5) LIA, ILMA	CVP >>>	6	9,5	Positive				
(6) Immunoblotting	CVP >>>	9	14	Positive				
(99) Another measurement principle	CVP >>>	2	3,2	Positive				
Sample B4		63				63	62	98
(2) EIA methods	CVP >>>	45	71	Negative				
		1	1,6	Positive				
(5) LIA, ILMA	CVP >>>	6	9,5	Negative				
(6) Immunoblotting	CVP >>>	9	14	Negative				
(99) Another measurement principle	CVP >>>	2	3,2	Negative				
Set 5								
(591) anti-nukleosomes IgG		54				54	54	100
Sample A5		54				54	54	100
(2) EIA methods	CVP >>>	41	76	Positive				
(6) Immunoblotting	CVP >>>	13	24	Positive				
Sample B5		54				54	54	100
(2) EIA methods	CVP >>>	41	76	Negative				
(6) Immunoblotting	CVP >>>	13	24	Negative				